van Klaveren Sjors, Hassan Mujtaba, Håkansson Maria, Johnsson Richard E, Larsson Jessica, Jakopin Žiga, Anderluh Marko, Leffler Hakon, Tomašič Tihomir, Nilsson Ulf J
Department of Chemistry, Faculty of Science, Lund University, Naturvetarvägen 14, 223 62, Lund, Sweden.
Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
ACS Med Chem Lett. 2024 Jul 22;15(8):1319-1324. doi: 10.1021/acsmedchemlett.4c00212. eCollection 2024 Aug 8.
Galectin-8 contains two different carbohydrate recognition domains (CRDs). Selective inhibitors for at least one CRD are desirable for galectin-8 biology studies and potentially for pharmacological purposes. Structure-guided design led to the discovery of potent and selective glycomimetic-heterocycle hybrid ligands, with a 4-(-bromophenyl)phthalazinone derivative displaying a 34 μM for galectin-8N (N-terminal CRD), no binding to galectin-8C (C-terminal CRD), -1, -3, -4N, -7, -9C, or -9N, and >40-fold selectivity over galectin-4C. Selectivity was achieved with the halogenated 4-phenylphthalazinone moiety occupying a galectin-8N-specific sub-pocket. A 1.30 Å resolution X-ray structure revealed the phthalazinone moiety stacking with Arg45 and the 4-bromophenyl moiety stacking both Arg59 and Tyr141 of galectin-8N. Physicochemical and ADME studies revealed a desirable LogD, which also translated to good passive permeability. The chemical, microsome, and plasma stability support these compounds as promising tool compounds and candidates for hit-to-lead optimization.
半乳糖凝集素-8包含两个不同的碳水化合物识别结构域(CRD)。对于半乳糖凝集素-8生物学研究以及潜在的药理学目的而言,至少针对一个CRD的选择性抑制剂是很有必要的。基于结构的设计促成了强效且选择性的糖模拟物-杂环混合配体的发现,其中一种4-(-溴苯基)酞嗪酮衍生物对半乳糖凝集素-8N(N端CRD)的解离常数为34 μM,不与半乳糖凝集素-8C(C端CRD)、-1、-3、-4N、-7、-9C或-9N结合,并且对半乳糖凝集素-4C的选择性超过40倍。通过卤代4-苯基酞嗪酮部分占据半乳糖凝集素-8N特有的亚口袋实现了选择性。分辨率为1.30 Å的X射线结构显示,酞嗪酮部分与半乳糖凝集素-8N的精氨酸45堆积,4-溴苯基部分与半乳糖凝集素-8N的精氨酸59和酪氨酸141都发生堆积。物理化学和药物代谢动力学研究显示出理想的脂水分配系数,这也转化为良好的被动通透性。化学稳定性以及在微粒体和血浆中的稳定性表明,这些化合物有望成为工具化合物以及用于从苗头化合物到先导化合物优化的候选物。